×
Indication and Limitations of Use
Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.
This website is intended for US Healthcare Professionals

A New Direction in SHPT

Rayaldee® is the first and only extended-release prohormone of the active form of vitamin D3
that raises 25-hydroxyvitamin D and lowers iPTH levels in patients with stage 3 or 4 CKD.1